These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
306 related items for PubMed ID: 27797594
21. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging. Hekman MCH, Boerman OC, Bos DL, Massuger LFAG, Weil S, Grasso L, Rybinski KA, Oosterwijk E, Mulders PFA, Rijpkema M. Mol Pharm; 2017 Oct 02; 14(10):3457-3463. PubMed ID: 28826214 [Abstract] [Full Text] [Related]
26. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. N Engl J Med; 2023 Dec 07; 389(23):2162-2174. PubMed ID: 38055253 [Abstract] [Full Text] [Related]
30. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer. Kokori E, Olatunji G, Komolafe R, Abraham IC, Ukoaka B, Samuel O, Ayodeji A, Ogunbowale I, Ezenwoba C, Aderinto N. Medicine (Baltimore); 2024 May 17; 103(20):e38132. PubMed ID: 38758856 [Abstract] [Full Text] [Related]
31. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Kamen BA, Smith AK. Cancer Chemother Pharmacol; 2012 Jul 17; 70(1):113-20. PubMed ID: 22644798 [Abstract] [Full Text] [Related]
35. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF. Mol Cancer Ther; 2018 Dec 17; 17(12):2665-2675. PubMed ID: 30262588 [Abstract] [Full Text] [Related]
36. Enthusiasm for antibody-drug conjugates. Tuma RS. J Natl Cancer Inst; 2011 Oct 19; 103(20):1493-4. PubMed ID: 21972230 [No Abstract] [Full Text] [Related]
37. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Birrer MJ, Betella I, Martin LP, Moore KN. Oncologist; 2019 Apr 19; 24(4):425-429. PubMed ID: 30635448 [Abstract] [Full Text] [Related]